Home » Genomic Health Uses Tecan Workstations to Automate Cancer Assay Development

Genomic Health Uses Tecan Workstations to Automate Cancer Assay Development

Aug 08, 2007
NEW YORK (GenomeWeb News) - Genomic Health is using Tecan’s liquid-handling workstations to automate the developmental process for its cancer recurrence assays, Tecan said this week.
 
Genomic Health markets Oncotype DX, a gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in early-stage breast cancer patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.